Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172412 | 0.86 | GABRA1 (0.43) | GABRA1GABRB2HTR1ATAAR1KCNH2 | |
| SCHEMBL27829682 | 0.85 | GABRA1 (0.46) | GABRA1GABRB2HTR1ATAAR1KCNH2 | |
| SCHEMBL30831845 | 0.84 | GABRA1 (0.46) | GABRA1GABRB2HTR1ATAAR1KCNH2 | |
| SCHEMBL21768207 | 0.84 | GABRA1 (0.46) | GABRA1GABRB2HTR1ATAAR1KCNH2 | |
| Ammonia Solution, Strong SCHEMBL17239637 | 0.83 | GABRA1 (0.44) | GABRA1GABRB2HTR1ATAAR1KCNH2 | |
| Chloromethane SCHEMBL27971188 | 0.81 | GABRA1 (0.59) | GABRA1GABRB2HTR1ATAAR1KCNH2 | |
| SCHEMBL245773 | 0.80 | GABRA1 (0.57) | GABRA1GABRB2HTR1ATAAR1KCNH2 | |
| SCHEMBL234202 | 0.80 | TSHR (0.39) | GABRA1GABRB2TAAR1ALDH1A1TSHR | |
| SCHEMBL7477512 | 0.80 | CLCN2 (0.50) | GABRA1GABRB2ALDH1A1TP53LMNA | |
| SCHEMBL9228420 | 0.80 | GABRA1 (0.38) | GABRA1GABRB2HTR1ATAAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011039-A | Large-steric-hindrance triazole carbene monodentate palladium compound containing surplus N, N chelating ligand, and preparation method and application thereof | 江苏科技大学 | 2026-05-12 | — | — | CN | disclosed |
| EP-2217576-B1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | UNIV MICHIGAN (US) | 2016-05-11 | — | — | EP | disclosed |
| US-8759340-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-24 | — | — | US | disclosed |
| US-8673897-B2 | Benzodiazepinone compounds and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-17 | — | — | US | disclosed |
| US-8461153-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120232067-A1 | BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2470020-A1 | BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME | The Regents of the University of Michigan (US) | 2012-07-04 | — | — | EP | disclosed |
| US-8188072-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120040971-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2217576-A2 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | The Regents of the University of Michigan (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061916-A2 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | disclosed |
| EP-1073657-B1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRAZENECA AB (SE) | 2005-12-07 | — | — | EP | disclosed |
| CN-1165535-C | Imidazo pyridine derivatives which inhibit gastric acid secretion | — | 2004-09-08 | — | — | CN | disclosed |
| US-6313137-B1 | FOR THERAPY AND PROPHYLAXIS OF GASTROINTESTINAL INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2001-11-06 | — | — | US | disclosed |
| CN-1307577-A | Imidazo pyridine derivatives which inhibit gastric acid secretion | ASTRA ZENECA AKTIEBOLAG (SE) | 2001-08-08 | — | — | CN | disclosed |
| EP-1073657-A1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | AstraZeneca AB (SE) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055706-A9 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRA AB (SE) | 2000-03-16 | — | — | WO | disclosed |
| WO-1999055706-A1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRAZENECA AB (SE) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040971-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | GABRA1 210/4885GABRB2 231/4885HTR1A 65/4885 |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | GABRA1 210/4885GABRB2 231/4885HTR1A 65/4885 |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | GABRA1 210/4885GABRB2 231/4885HTR1A 65/4885 |
| US-20120232067-A1 | BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME | TPH1, GABBR1, RORC | GABRA1 22/4885GABRB2 55/4885HTR1A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.